JP2022529061A5 - - Google Patents
Info
- Publication number
- JP2022529061A5 JP2022529061A5 JP2021561927A JP2021561927A JP2022529061A5 JP 2022529061 A5 JP2022529061 A5 JP 2022529061A5 JP 2021561927 A JP2021561927 A JP 2021561927A JP 2021561927 A JP2021561927 A JP 2021561927A JP 2022529061 A5 JP2022529061 A5 JP 2022529061A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- hydroxyl
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/083376 | 2019-04-19 | ||
| CN2019083376 | 2019-04-19 | ||
| PCT/CN2020/085338 WO2020211839A1 (en) | 2019-04-19 | 2020-04-17 | Jak1 selective kinase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529061A JP2022529061A (ja) | 2022-06-16 |
| JP2022529061A5 true JP2022529061A5 (https=) | 2024-07-08 |
| JP7555959B2 JP7555959B2 (ja) | 2024-09-25 |
Family
ID=72837031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561927A Active JP7555959B2 (ja) | 2019-04-19 | 2020-04-17 | Ｊａｋ１選択的キナーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12606544B2 (https=) |
| EP (1) | EP3956322B1 (https=) |
| JP (1) | JP7555959B2 (https=) |
| KR (1) | KR20220003537A (https=) |
| CN (1) | CN113710664B (https=) |
| AR (1) | AR118729A1 (https=) |
| AU (1) | AU2020258619C1 (https=) |
| BR (1) | BR112021020964A2 (https=) |
| CA (1) | CA3134174A1 (https=) |
| DK (1) | DK3956322T3 (https=) |
| ES (1) | ES3031576T3 (https=) |
| MX (1) | MX2021012749A (https=) |
| PT (1) | PT3956322T (https=) |
| TW (1) | TWI910107B (https=) |
| WO (1) | WO2020211839A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022111499A1 (zh) * | 2020-11-26 | 2022-06-02 | 深圳铂立健医药有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198900B2 (en) * | 2011-11-10 | 2015-12-01 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using JAK inhibitors |
| JP6767491B2 (ja) | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| ES2938648T3 (es) * | 2017-01-17 | 2023-04-13 | Astrazeneca Ab | Inhibidores selectivos de JAK1 |
| CA3113732C (en) * | 2018-09-21 | 2023-07-11 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Aromatic heterocyclic compound with kinase inhibitory activity |
-
2020
- 2020-04-17 MX MX2021012749A patent/MX2021012749A/es unknown
- 2020-04-17 AR ARP200101101A patent/AR118729A1/es unknown
- 2020-04-17 JP JP2021561927A patent/JP7555959B2/ja active Active
- 2020-04-17 CN CN202080029899.3A patent/CN113710664B/zh active Active
- 2020-04-17 WO PCT/CN2020/085338 patent/WO2020211839A1/en not_active Ceased
- 2020-04-17 BR BR112021020964A patent/BR112021020964A2/pt unknown
- 2020-04-17 KR KR1020217036576A patent/KR20220003537A/ko not_active Ceased
- 2020-04-17 CA CA3134174A patent/CA3134174A1/en active Pending
- 2020-04-17 ES ES20790639T patent/ES3031576T3/es active Active
- 2020-04-17 AU AU2020258619A patent/AU2020258619C1/en active Active
- 2020-04-17 EP EP20790639.7A patent/EP3956322B1/en active Active
- 2020-04-17 US US17/604,442 patent/US12606544B2/en active Active
- 2020-04-17 TW TW109112994A patent/TWI910107B/zh active
- 2020-04-17 PT PT207906397T patent/PT3956322T/pt unknown
- 2020-04-17 DK DK20790639.7T patent/DK3956322T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529061A5 (https=) | ||
| JP6434416B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2014505107A5 (https=) | ||
| US20150018396A1 (en) | Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist | |
| JP2019509276A5 (https=) | ||
| JP2010524932A5 (https=) | ||
| JP2008531714A (ja) | 不安障害の治療用及び／又は予防用の医薬組成物 | |
| RU2017105470A (ru) | Способы лечения парамиксовирусов | |
| JP2005509024A5 (https=) | ||
| CN104024217B (zh) | 用于治疗或预防与内分泌功能障碍相关的症状的三环含氨基化合物 | |
| JP2019505529A5 (https=) | ||
| JP2008538741A (ja) | 鬱病の治療用及び／又は予防用の医薬組成物 | |
| JP2017504635A5 (https=) | ||
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| JP2023512664A5 (https=) | ||
| JP2018522861A5 (https=) | ||
| RU2015146417A (ru) | Пероральная фармацевтическая композиция для профилактики или лечения синдрома "сухого глаза", содержащая ребамипид или его предшественник | |
| RU2014119711A (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| WO2016101898A1 (zh) | 3-[(苯并[d][1，3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用 | |
| JP2007518798A5 (https=) | ||
| CA2567797A1 (en) | Peptidic vasopressin receptor agonists | |
| JP2020510061A5 (https=) | ||
| DK1634595T3 (da) | N-Phenylbenzamidderivater som medikamenter til behandling af kronisk obstruktiv lungesygdom (KOL) | |
| JP2006524677A5 (https=) |